Do you want to read an article? Please log in or register.
Brigimadlin Versus Doxorubicin in Advanced Dedifferentiated Liposarcoma: Efficacy, Safety and Translational Data from Brightline-1, a Randomized Phase 2/3 Trial
Sarcoma
Related content
Non-Malignant Blood Disorders
Efficacy and Safety of Subcutaneous Efgartigimod PH20 in Adults With Primary Immune Thrombocytopenia (ADVANCE SC): A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 3 Trial
Am J Hematol
Cooper N, Broome CM, Miyakawa Y, McDonald V, Al-Samkari H, Khelif A, Cataland SR, Barcellini W, Yang R, Mei H, Matthijssens F, Hultberg A, Ciurlia G, Gandini D, Ayguasanosa J, De Beuf K, Pastouret S, Ghanima W, Rodeghiero F, Bussel JB, ADVANCE SC Investigator Trial Group
doi: 10.1002/ajh.70303
Endocrine and Neuroendocrine Tumors (NET)
(177)Lu-Dotatate versus high-dose long-acting octreotide for the treatment of patients with advanced, grade 1-2, well-differentiated gastroenteropancreatic neuroendocrine tumours (XT-XTR008-3-01): an open-label, randomised, phase III trial
Ann Oncol
Xu J, Chen J, Song S, Song L, Wang R, Hao J, Du X, Cao D, Gao Y, Lan X, Yang A, Miao W, Xu H, Chen Y, Li L, Shi H, Yuan X, Ye F, Wang J, Xu N, Han X, Li X, Huang R, Zhang T, Li E, Wang R, Zhou Y, Chen H, Zhu X, Zhao J, Su X, Cui Y, Ren P, Wang P
doi: 10.1016/j.annonc.2025.08.3758
Breast Cancer
Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 10-year efficacy and late normal tissue effects from a multicentre, open-label, non-inferiority, phase 3, randomised controlled trial and 5-year efficacy results from a randomised axillary substudy
Lancet Oncol
Brunt AM, Cafferty FH, Kirby AM, Patel J, Sydenham MA, Haviland JS, Griffin S, Chivardi C, Fleming H, Coles CE, Bloomfield DJ, Chan C, Cleator S, Goodman A, Griffin CL, Kirwan CC, Nabi Z, Sawyer E, Somaiah N, Syndikus I, Venables K, Wheatley DA, Yarnold JR, Bliss JM
doi: 10.1016/S1470-2045(26)00076-8
Lung, Respiratory and Thoracic Cancer
Cemiplimab Plus Chemotherapy Versus Chemotherapy in Advanced NSCLC: 5-year Results From Phase 3 EMPOWER-Lung 3 Part 2 Trial
J Thorac Oncol
Baramidze A, Makharadze T, Gogishvili M, Melkadze T, Giorgadze D, Penkov K, Laktionov K, Nemsadze G, Nechaeva M, Rozhkova I, Kalinka E, Li Y, McIntyre DAG, Jia X, Perez J, Kaul M, Lowy I, Pouliot JF, Chua S, Kim E, Seebach F, Magnan H
doi: 10.1016/j.jtho.2026.103980
Breast Cancer
Bireociclib Plus Fulvestrant in Advanced Breast Cancer After Endocrine Progression: The BRIGHT-2 Phase 3 Randomized Clinical Trial
JAMA Oncol
Wang J, Zhang Q, Li H, Tong Z, Ouyang Q, Li H, Teng Y, Wang B, Sun T, Wang J, Li W, Niu Z, Li H, Gong C, Wang S, Wang X, Wu X, Liu N, Yu G, Hu Y, Wang Q, Duan X, Yang F, Wang L, Xu B
doi: 10.1001/jamaoncol.2026.0318
Genitourinary Cancer
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial
Ann Oncol
Choueiri TK, Albigès L, McDermott DF, Hammers HJ, Escudier B, Burotto M, Plimack ER, Porta C, George S, Powles T, Donskov F, Atkins MB, Gurney H, Kollmannsberger CK, Grimm MO, Barrios C, Castellano D, Grünwald V, Tomita Y, Rini BI, Jiang R, van Kooten Losio M, Lee CW, Tannir NM, Motzer RJ
doi: 10.1016/j.annonc.2026.02.017
Gynecologic Cancer
Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS-1): A multicenter, randomized, double-blind, placebo-controlled phase 3 trial
CA Cancer J Clin
Wu L, Wang J, Li Q, Wang D, Zhang C, Tang J, Zhang G, Hao M, Yao D, Gao Q, Zhang Y, An R, Yin R, Wang L, Xia B, Zhou Q, Yang H, Zhu J, Jiang K, Chen Z, Wu Q, Duan W, Huang Y, Zhang H, Wei S, Li G, Meng Y, Wang K, Yang X, Huang X, Pan L, Yu J, Lou G, Zhang Y, Zhou H, Guo X, Yang H, Cheng X, Li X, Wang W, Zhao H, Li Y, Yang Y, Lin A, Cheng W, Chen L, Xie X, Di W, Hu Y, Chen M, Wen H, Cai L, Wu X, Lin Z, Wang Q, Yang X, Li N
doi: 10.3322/caac.70042
RECOMMENDED
Breast Cancer
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer: Updated Efficacy Results from the phase 3 EMBER-3 trial
★ 2
Recommended by
Prof. Dr Beat Thürlimann, Faculty Member
Ann Oncol
Jhaveri KL, Neven P, Casalnuovo ML, Kim SB, Tokunaga E, Aftimos P, Saura C, O'Shaughnessy J, Harbeck N, Carey LA, Curigliano G, Watanabe J, Lim E, Huang J, Qingyuan Z, Llombart-Cussac A, Huang C, Desai B, Limay Y, Wang XA, Cao S, Bidard FC
doi: 10.1016/j.annonc.2025.11.018
Breast Cancer
CDK4/6 inhibitors plus endocrine therapy versus endocrine monotherapy in hormone receptor-positive, HER2-negative advanced breast cancer: a reconstructed individual patient data meta-analysis of phase 3 randomised controlled trials
Lancet Oncol
Beshr MS, Fahaid A, Shembesh RH, Valachis A, Lambertini M, Cortesi L, Alesawy AF, Abraheem A, Alsharedi M, Ali ME, Elkhanany A, Azim HA Jr, Velikova G, Elhadi M
doi: 10.1016/S1470-2045(26)00053-7